Novo Nordisk today announced topline results from a phase 1b/2a clinical trial with amycretin, a unimolecular GLP-1 and amylin receptor agonist intended for once weekly ...

Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to treat ...

One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...

Novo Nordisk's U.S.-listed shares are surging 9% Friday morning after the Danish drugmaker reported early stage results for ...

Novo Nordisk A/S soared the most since August after an experimental shot delivered as much as 22% weight loss in an ...

Jan. 23, 2025 — With the recent surge in popularity of weight loss drugs like Ozempic, altogether called GLP-1s, there has been renewed scientific interest in understanding how our bodies ...

A new weight loss drug from Novo Nordisk helped patients lose a large amount of weight, providing a boost for Novo in the ...

The Danish pharmaceutical giant reported positive early-stage results for its once weekly amycretin obesity drug.

Shares of Danish pharmaceutical giant Novo Nordisk surged close to 14% on Friday after the company announced positive results ...

One of the glaring numbers in this loss for the Tigers is in the turnover column. Ball security has been an issue for them this season and it continued against the Aggies. After finishing the ...

Novo Nordisk’s subcutaneous form of amycretin achieved estimated weight loss of 22% at six months in a Phase 1b/2a clinical ...

If you are underweight, you should not follow a weight-loss plan. The volunteers reduced their waist sizes by an average of 1 inch for every 4lb (1.81kg) they lost. So if you lose 1lb (0.45kg ...